-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Medical News, April 6th.
In recent years, domestic biomedical innovation and development have ushered in great prosperity.
The VIC model has become a business strategy pursued by pharmaceutical innovative companies.
Many breakthrough new drugs are realized through License-in (authorized introduction).
In recent years, domestic biomedical innovation and development have ushered in great prosperity.
The VIC model has become a business strategy pursued by pharmaceutical innovative companies.
Many breakthrough new drugs are realized through License-in (authorized introduction).
In the first quarter of 2021, the enthusiasm of the innovative drug R&D and commercial cooperation market continued in 2020.
The Pharmaceutical Economic News found that the number of license-in projects in just three months has reached 24; at the same time, it is accompanied by the R&D and innovation of Chinese pharmaceutical companies.
The strength continues to improve, and the number of license-out cases and amounts are also increasing.
The Pharmaceutical Economic News found that the number of license-in projects in just three months has reached 24; at the same time, it is accompanied by the R&D and innovation of Chinese pharmaceutical companies.
The strength continues to improve, and the number of license-out cases and amounts are also increasing.
Innovative products soar
Significant acceleration in the introduction of authorization
License-in, as a conventional new drug cooperation model, skips the long process of early internal development, quickly integrates external collaboration or complementary resources, and brings the company a product line that meets the overall strategic plan as soon as possible, and has achieved a number of license-in products.
The leading domestic innovative drug companies have also aroused the focus of the entire industry on the license-in model.
The leading domestic innovative drug companies have also aroused the focus of the entire industry on the license-in model.
From January to March 2021, after sorting out, it is found that Chinese local pharmaceutical innovation companies are still the core force of License-in, including a batch of leading companies such as BeiGene, Zai Lab, Fuhong Henlius, and Sidi Medicine, etc.
The Biopharma/Biotech company will be fully fired at the beginning of 2021.
The Biopharma/Biotech company will be fully fired at the beginning of 2021.
Not only that, a number of large local industrial companies, including Hengrui Pharmaceuticals, Hausen Pharmaceuticals, Qilu Pharmaceuticals, Yangtze River, Simcere Pharmaceuticals, Harbin Pharmaceutical Group, etc.
, are also actively optimizing their product pipelines through license-in methods.
Integrate innovative resources.
, are also actively optimizing their product pipelines through license-in methods.
Integrate innovative resources.
Specific to the disease field of the License-in project , tumors are still the most popular field, and the fields of digestion, autoimmunity, and ophthalmology have also been focused on the layout of enterprises.
In addition, unmet clinical needs in such subdivisions as vaccines, anti-infectives, and anti-viruses have also attracted industry attention, and they all have obvious clinical treatment advantages.
In addition, unmet clinical needs in such subdivisions as vaccines, anti-infectives, and anti-viruses have also attracted industry attention, and they all have obvious clinical treatment advantages.
It is worth noting that in the first quarter, BeiGene, Zai Lab, Fuhong Henlius, Liantuo Biotech, and Sidi Medicine all introduced two products, while BeiGene and Haisco have both product introductions and product authorizations.
Go to sea.
Go to sea.
In the first quarter of more than 300 million US dollars of transactions, BeiGene and mRNA therapy company Strand Therapeutics announced a US$320 million cooperation to develop and commercialize Strand new and multifunctional mRNA therapies in solid tumors; and Zai Lab and Zai Lab and Strand Therapeutics Turning Point Therapeutics announced that it has reached a strategic cooperation of US$361 million.
Zai Lab has obtained the exclusive right to develop and commercialize the MET/SRC/CSF1R inhibitor TPX-0022 in Greater China.
Zai Lab has obtained the exclusive right to develop and commercialize the MET/SRC/CSF1R inhibitor TPX-0022 in Greater China.
License in transaction summary for the first quarter
Local R&D upgrade
Value products go to sea to find their way
The strength of China's independent innovative drugs is constantly improving, and its sights are aimed at overseas markets.
There are many ways to "go overseas" for innovative drugs, and License-out is one of the important ones.
Reaching a license-out agreement with international pharmaceutical companies is not only an important manifestation of the strength of innovative drug companies, but also an important channel for independent innovative drugs to enter the international market.
There are many ways to "go overseas" for innovative drugs, and License-out is one of the important ones.
Reaching a license-out agreement with international pharmaceutical companies is not only an important manifestation of the strength of innovative drug companies, but also an important channel for independent innovative drugs to enter the international market.
Chidamide, independently developed by Shenzhen Chipset, is a pioneer in the external authorization of Chinese new drugs.
In 2006, it transferred global patents other than China to Huya for US$28 million, becoming the first company in China to license innovative drugs externally.
Since then, Chinese pharmaceutical companies have more diversified overseas rights and interests, including commercial promotion, development and commercialization of technology platforms and clinical products.
In 2006, it transferred global patents other than China to Huya for US$28 million, becoming the first company in China to license innovative drugs externally.
Since then, Chinese pharmaceutical companies have more diversified overseas rights and interests, including commercial promotion, development and commercialization of technology platforms and clinical products.
In recent years, there have been more and more cases of cooperation between local pharmaceutical companies and foreign pharmaceutical companies on new drugs.
Behind the increasing activity of License-in and License-out is the gradual improvement of China's new drug research and development capabilities and the recognition of overseas markets.
Behind the increasing activity of License-in and License-out is the gradual improvement of China's new drug research and development capabilities and the recognition of overseas markets.
From January to March 2021, a total of 7 products were authorized to go overseas.
In addition to PD-1 and biosimilar products, Luye Pharma’s new drug Lismin Transdermal Patch for the treatment of Alzheimer’s disease, China Biotech Highly selective inhibitors of Rho/Rho-related coiled-coil forming protein kinase 2 (ROCK2), as well as Hesco’s oral selective tyrosine kinase 2 inhibitors, and Kelun Pharmaceutical’s small-molecule tumor targeting RET Kinase inhibitors are all very innovative.
In addition to PD-1 and biosimilar products, Luye Pharma’s new drug Lismin Transdermal Patch for the treatment of Alzheimer’s disease, China Biotech Highly selective inhibitors of Rho/Rho-related coiled-coil forming protein kinase 2 (ROCK2), as well as Hesco’s oral selective tyrosine kinase 2 inhibitors, and Kelun Pharmaceutical’s small-molecule tumor targeting RET Kinase inhibitors are all very innovative.
While the ecological environment of domestic innovative drugs is gradually being constructed and mature, a number of outstanding companies have also begun to rapidly narrow the gap with the world's leading companies in clinical research.
In terms of transaction volume, in March alone, the total transaction amount exceeded 10 billion yuan, of which the total amount of 3 license-in transactions that occurred on March 29 exceeded 3 billion yuan; in addition, there were 10 domestic pharmaceutical company licenses in March.
The transaction amount of in/out transaction items reached tens of millions of yuan.
In terms of transaction volume, in March alone, the total transaction amount exceeded 10 billion yuan, of which the total amount of 3 license-in transactions that occurred on March 29 exceeded 3 billion yuan; in addition, there were 10 domestic pharmaceutical company licenses in March.
The transaction amount of in/out transaction items reached tens of millions of yuan.
Summary of license out transactions in the first quarter
Medical News, April 6th.
In recent years, domestic biomedical innovation and development have ushered in great prosperity.
The VIC model has become a business strategy pursued by pharmaceutical innovative companies.
Many breakthrough new drugs are realized through License-in (authorized introduction).
In recent years, domestic biomedical innovation and development have ushered in great prosperity.
The VIC model has become a business strategy pursued by pharmaceutical innovative companies.
Many breakthrough new drugs are realized through License-in (authorized introduction).
In the first quarter of 2021, the enthusiasm of the innovative drug R&D and commercial cooperation market continued in 2020.
The Pharmaceutical Economic News found that the number of license-in projects in just three months has reached 24; at the same time, it is accompanied by the R&D and innovation of Chinese pharmaceutical companies.
The strength continues to improve, and the number of license-out cases and amounts are also increasing.
The Pharmaceutical Economic News found that the number of license-in projects in just three months has reached 24; at the same time, it is accompanied by the R&D and innovation of Chinese pharmaceutical companies.
The strength continues to improve, and the number of license-out cases and amounts are also increasing.
Innovative products soar
Significant acceleration in the introduction of authorization
License-in, as a conventional new drug cooperation model, skips the long process of early internal development, quickly integrates external collaboration or complementary resources, and brings the company a product line that meets the overall strategic plan as soon as possible, and has achieved a number of license-in products.
The leading domestic innovative drug companies have also aroused the focus of the entire industry on the license-in model.
The leading domestic innovative drug companies have also aroused the focus of the entire industry on the license-in model.
From January to March 2021, after sorting out, it is found that Chinese local pharmaceutical innovation companies are still the core force of License-in, including a batch of leading companies such as BeiGene, Zai Lab, Fuhong Henlius, and Sidi Medicine, etc.
The Biopharma/Biotech company will be fully fired at the beginning of 2021.
The Biopharma/Biotech company will be fully fired at the beginning of 2021.
Not only that, a number of large local industrial companies, including Hengrui Pharmaceuticals, Hausen Pharmaceuticals, Qilu Pharmaceuticals, Yangtze River, Simcere Pharmaceuticals, Harbin Pharmaceutical Group, etc.
, are also actively optimizing their product pipelines through license-in methods.
Integrate innovative resources.
, are also actively optimizing their product pipelines through license-in methods.
Integrate innovative resources.
Specific to the disease field of the License-in project , tumors are still the most popular field, and the fields of digestion, autoimmunity, and ophthalmology have also been focused on the layout of enterprises.
In addition, unmet clinical needs in such subdivisions as vaccines, anti-infectives, and anti-viruses have also attracted industry attention, and they all have obvious clinical treatment advantages.
In addition, unmet clinical needs in such subdivisions as vaccines, anti-infectives, and anti-viruses have also attracted industry attention, and they all have obvious clinical treatment advantages.
It is worth noting that in the first quarter, BeiGene, Zai Lab, Fuhong Henlius, Liantuo Biotech, and Sidi Medicine all introduced two products, while BeiGene and Haisco have both product introductions and product authorizations.
Go to sea.
Go to sea.
In the first quarter of more than 300 million US dollars of transactions, BeiGene and mRNA therapy company Strand Therapeutics announced a US$320 million cooperation to develop and commercialize Strand new and multifunctional mRNA therapies in solid tumors; and Zai Lab and Zai Lab and Strand Therapeutics Turning Point Therapeutics announced that it has reached a strategic cooperation of US$361 million.
Zai Lab has obtained the exclusive right to develop and commercialize the MET/SRC/CSF1R inhibitor TPX-0022 in Greater China.
Zai Lab has obtained the exclusive right to develop and commercialize the MET/SRC/CSF1R inhibitor TPX-0022 in Greater China.
License in transaction summary for the first quarter
Local R&D upgrade
Value products go to sea to find their way
The strength of China's independent innovative drugs is constantly improving, and its sights are aimed at overseas markets.
There are many ways to "go overseas" for innovative drugs, and License-out is one of the important ones.
Reaching a license-out agreement with international pharmaceutical companies is not only an important manifestation of the strength of innovative drug companies, but also an important channel for independent innovative drugs to enter the international market.
There are many ways to "go overseas" for innovative drugs, and License-out is one of the important ones.
Reaching a license-out agreement with international pharmaceutical companies is not only an important manifestation of the strength of innovative drug companies, but also an important channel for independent innovative drugs to enter the international market.
Chidamide, independently developed by Shenzhen Chipset, is a pioneer in the external authorization of Chinese new drugs.
In 2006, it transferred global patents other than China to Huya for US$28 million, becoming the first company in China to license innovative drugs externally.
Since then, Chinese pharmaceutical companies have more diversified overseas rights and interests, including commercial promotion, development and commercialization of technology platforms and clinical products.
In 2006, it transferred global patents other than China to Huya for US$28 million, becoming the first company in China to license innovative drugs externally.
Since then, Chinese pharmaceutical companies have more diversified overseas rights and interests, including commercial promotion, development and commercialization of technology platforms and clinical products.
In recent years, there have been more and more cases of cooperation between local pharmaceutical companies and foreign pharmaceutical companies on new drugs.
Behind the increasing activity of License-in and License-out is the gradual improvement of China's new drug research and development capabilities and the recognition of overseas markets.
Behind the increasing activity of License-in and License-out is the gradual improvement of China's new drug research and development capabilities and the recognition of overseas markets.
From January to March 2021, a total of 7 products were authorized to go overseas.
In addition to PD-1 and biosimilar products, Luye Pharma’s new drug Lismin Transdermal Patch for the treatment of Alzheimer’s disease, China Biotech Highly selective inhibitors of Rho/Rho-related coiled-coil forming protein kinase 2 (ROCK2), as well as Hesco’s oral selective tyrosine kinase 2 inhibitors, and Kelun Pharmaceutical’s small-molecule tumor targeting RET Kinase inhibitors are all very innovative.
In addition to PD-1 and biosimilar products, Luye Pharma’s new drug Lismin Transdermal Patch for the treatment of Alzheimer’s disease, China Biotech Highly selective inhibitors of Rho/Rho-related coiled-coil forming protein kinase 2 (ROCK2), as well as Hesco’s oral selective tyrosine kinase 2 inhibitors, and Kelun Pharmaceutical’s small-molecule tumor targeting RET Kinase inhibitors are all very innovative.
While the ecological environment of domestic innovative drugs is gradually being constructed and mature, a number of outstanding companies have also begun to rapidly narrow the gap with the world's leading companies in clinical research.
In terms of transaction volume, in March alone, the total transaction amount exceeded 10 billion yuan, of which the total amount of 3 license-in transactions that occurred on March 29 exceeded 3 billion yuan; in addition, there were 10 domestic pharmaceutical company licenses in March.
The transaction amount of in/out transaction items reached tens of millions of yuan.
In terms of transaction volume, in March alone, the total transaction amount exceeded 10 billion yuan, of which the total amount of 3 license-in transactions that occurred on March 29 exceeded 3 billion yuan; in addition, there were 10 domestic pharmaceutical company licenses in March.
The transaction amount of in/out transaction items reached tens of millions of yuan.
Summary of license out transactions in the first quarter
Medical News, April 6th.
In recent years, domestic biomedical innovation and development have ushered in great prosperity.
The VIC model has become a business strategy pursued by pharmaceutical innovative companies.
Many breakthrough new drugs are realized through License-in (authorized introduction).
In recent years, domestic biomedical innovation and development have ushered in great prosperity.
The VIC model has become a business strategy pursued by pharmaceutical innovative companies.
Many breakthrough new drugs are realized through License-in (authorized introduction).
In the first quarter of 2021, the enthusiasm of the innovative drug R&D and commercial cooperation market continued in 2020.
The Pharmaceutical Economic News found that the number of license-in projects in just three months has reached 24; at the same time, it is accompanied by the R&D and innovation of Chinese pharmaceutical companies.
The strength continues to improve, and the number of license-out cases and amounts are also increasing.
Pharmaceutical Pharmaceutical Pharmaceutical Enterprise Enterprise EnterpriseThe Pharmaceutical Economic News found that the number of license-in projects in just three months has reached 24; at the same time, it is accompanied by the R&D and innovation of Chinese pharmaceutical companies.
The strength continues to improve, and the number of license-out cases and amounts are also increasing.
Innovative products soar
Innovative products soar Significant acceleration in the introduction of authorization
Significant acceleration in the introduction of authorization License-in, as a conventional new drug cooperation model, skips the long process of early internal development, quickly integrates external collaboration or complementary resources, and brings the company a product line that meets the overall strategic plan as soon as possible, and has achieved a number of license-in products.
The leading domestic innovative drug companies have also aroused the focus of the entire industry on the license-in model.
The leading domestic innovative drug companies have also aroused the focus of the entire industry on the license-in model.
From January to March 2021, after sorting out, it is found that Chinese local pharmaceutical innovation companies are still the core force of License-in, including a batch of leading companies such as BeiGene, Zai Lab, Fuhong Henlius, and Sidi Medicine, etc.
The Biopharma/Biotech company will be fully fired at the beginning of 2021.
The Biopharma/Biotech company will be fully fired at the beginning of 2021.
Not only that, a number of large local industrial companies, including Hengrui Pharmaceuticals, Hausen Pharmaceuticals, Qilu Pharmaceuticals, Yangtze River, Simcere Pharmaceuticals, Harbin Pharmaceutical Group, etc.
, are also actively optimizing their product pipelines through license-in methods.
Integrate innovative resources.
, are also actively optimizing their product pipelines through license-in methods.
Integrate innovative resources.
Specific to the disease field of the License-in project , tumors are still the most popular field, and the fields of digestion, autoimmunity, and ophthalmology have also been focused on the layout of enterprises.
In addition, unmet clinical needs in such subdivisions as vaccines, anti-infectives, and anti-viruses have also attracted industry attention, and they all have obvious clinical treatment advantages.
Disease disease disease tumor tumor tumorIn addition, unmet clinical needs in such subdivisions as vaccines, anti-infectives, and anti-viruses have also attracted industry attention, and they all have obvious clinical treatment advantages.
，，、、、、，。
3，mRNAStrand Therapeutics3.
2，Strand、mRNA；Turning Point Therapeutics3.
61，MET/SRC/CSF1RTPX-0022。
2，Strand、mRNA；Turning Point Therapeutics3.
61，MET/SRC/CSF1RTPX-0022。
License in
，。“”，License-out。License-out，。
，20062800，。，，、。
，。License-inLicense-out，，。
20211-3，7，PD-1，、Rho/Rho2（ROCK2），2、RET，。
，。，3，，3293License-in30；，310License in /out 。
License out
